Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.47 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.47 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.38 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
| ▸ | PRCP | P42785 | 5/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.38 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5838001 | 0.89 | KCNQ3 (0.44) | KCNQ3KCNQ2CHRNA7SMN1; SMN2TAAR1 | |
| SCHEMBL5717882 | 0.88 | KCNQ3 (0.43) | KCNQ3KCNQ2CHRNA7SMN1; SMN2TAAR1 | |
| Bicarbonate SCHEMBL5718065 | 0.87 | KCNQ3 (0.44) | KCNQ3KCNQ2CHRNA7SMN1; SMN2TAAR1 | |
| SCHEMBL5718061 | 0.86 | KCNQ3 (0.42) | KCNQ3KCNQ2CHRNA7SMN1; SMN2TAAR1 | |
| SCHEMBL5838749 | 0.86 | KCNQ3 (0.41) | KCNQ3KCNQ2CHRNA7SMN1; SMN2TAAR1 | |
| SCHEMBL5718074 | 0.85 | F2 (0.41) | KCNQ3KCNQ2CHRNA7SMN1; SMN2NR3C2 | |
| SCHEMBL5838390 | 0.85 | PRCP (0.42) | KCNQ3KCNQ2TAAR1PRCPKCNH2 | |
| SCHEMBL5838279 | 0.85 | PRCP (0.42) | KCNQ3KCNQ2TAAR1PRCPKCNH2 | |
| SCHEMBL5718078 | 0.82 | F2 (0.50) | KCNQ3KCNQ2SMN1; SMN2F2 | |
| SCHEMBL5837962 | 0.80 | KCNQ3 (0.37) | KCNQ3KCNQ2CHRNA7TAAR1NR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074780-B2 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-24 | — | — | US | disclosed |
| US-6649616-B2 | For therapy and prophylaxis of cardiovascular disorders caused by ischaemia | BAYER AKTIENGESELLSCHAFT (DE) | 2003-11-18 | — | — | US | disclosed |
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008881-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | KCNQ3 1604/4885KCNQ2 1282/4885CHRNA7 3454/4885 |
| US-20040122004-A1 | Substituted phenylcyclohexanecarboxamides and their use | TNNI3, PAH, P4HA1 | KCNQ3 1604/4885KCNQ2 1282/4885CHRNA7 3454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.